Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

Ítems similars

• First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
  per: Byrd, John C., et al.
  Publicat: (2018)
• Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
  per: Reiff, Sean D., et al.
  Publicat: (2018)
• Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
  per: Bond, David A, et al.
  Publicat: (2020)
• BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
  per: Lin, Victor S., et al.
  Publicat: (2020)
• The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation
  per: Reiff, Sean D., et al.
  Publicat: (2018)